Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

Phase 2

Completed

• Conditions: PCDH19-Related Epilepsy
• Interventions: Drug: Placebo; Drug: Ganaxolone

• Registration Number: NCT03865732
• Lead Sponsor: Marinus Pharmaceuticals

Brief Summary

A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in female children and young adults with genetically confirmed PCDH19 gene mutation.

Detailed Description

The Violet Study is a global, double-blind, placebo-controlled, Phase 2 clinical trial that plans to enroll approximately 25 female patients between the ages of 1 and 17 with a confirmed disease-related PCDH19 gene variant. Patients will undergo a baseline period before being randomized to receive, in addition to their existing anti-seizure treatment, either ganaxolone or placebo for 17 weeks. Following the treatment period, all patients that meet certain eligibility requirements will have the opportunity to receive ganaxolone in the open label phase of the study. The study's primary efficacy endpoint is percent reduction in seizures. Secondary outcome measures will include non-seizure-related endpoints to capture certain behavioral and sleep disturbances that have been seen in previous clinical studies with ganaxolone.

Study Timeline

• Study First Submitted: 2019-03-05
• Study First Submitted QC: 2019-03-05
• Study First Posted: 2019-03-07
• Study Start: 2019-05-17
• Primary Completion: 2021-01-19
• Results First Submitted: 2022-05-24
• Study Completion: 2022-06-20
• Results First Submitted QC: 2022-08-15
• Results First Posted: 2022-09-08
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-20
• Last Update Posted: 2023-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 29

Inclusion Criteria

• Molecular confirmation of a pathogenic or likely pathogenic PCDH19 variant
• Failure to control seizures despite 2 or more anti-seizure medications
• 12 seizures over a 12-week period of primary seizure types prior to screening
• On a stable regimen of concomitant AEDs, Ketogenic diets, and modified Atkins diet should be unchanged for 3 months prior to screening)

Read More

Exclusion Criteria

• Previous exposure to ganaxolone
• > 8 consecutive weeks of seizure freedom during the 12 weeks prior to screening
• Concurrent use of strong inducers or inhibitors of CYP3A4/5/7 is not permitted
• Use of tetrahydrocannabinol (THC) or non-approved cannabidiol (CBD) is prohibited during the double-blind phase
• Exposure to any other investigational drug within 30 days or fewer than 5 half-lives prior to screening

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	placebo suspension 3x's /day for 17 weeks
Ganaxolone	Ganaxolone	ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks

Primary Outcome Measures

Name	Time	Method
Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change)	End of the double-blind 17 week treatment period	Summary of 28-Day Seizure Frequency for Seizure Types through 17 week Post-Baseline Phase (Median Percent Change)

Secondary Outcome Measures

Name	Time	Method
Summary of 28-day Seizure Frequency for Subjects in the Biomarker-positive Stratum (Median Percent Change)	[Time Frame: End of the double-blind 17 week treatment period]	Summary of 28-day Seizure Frequency for Seizure Types for Subjects in the Biomarker-positive Stratum through 17 weeks (Median Percent Change)
50% Primary Seizure Reduction	End of the double-blind 17 week treatment period	Percent of subjects experiencing a greater than or equal to 50% reduction in 28-day primary seizure frequency relative to the 12-week baseline

Trial Locations

Locations (1)

Marinus Research Site; 🇵🇱 Krakow, Poland